Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin

NCT07560566 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT07560566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07560566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin
Lead sponsor
National Taiwan University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
December 9, 2025
Completion date
April 30, 2029
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hand foot skin syndrome, hepato cellular carcinoma (hcc)